The 2015 global production capacity of seasonal and pandemic influenza vaccine
The 2015 global production capacity of seasonal and pandemic influenza vaccine
复制标题
DOI：
10.1016/j.vaccine.2016.08.019
复制
发表时间：
2016-10-25
期刊：
影响因子：
5.5
通讯作者：
Torelli, Guido
中科院分区：
文献类型：
--
作者：
McLean, Kenneth A.;Goldin, Shoshanna;Torelli, Guido
流感疫苗的全球短缺和不公平获得一直是发展中国家关切的问题，一旦发生大流行，发展中国家将面临可怕的后果。全球流感疫苗行动计划（GAP）于2006年启动，旨在提高全球流感疫苗生产能力，以解决这些问题。人们普遍认识到，生产季节性流感疫苗的基础设施发展良好，可提高生产大流行性流感疫苗的能力。本文总结了对44家制造商进行的一项调查的结果，以评估其季节性流感和大流行性流感疫苗生产的生产能力。2006年启动差距》时，季节性和大流行性疫苗的全球生产能力估计分别为5亿剂和15亿剂。自2006年以来，能力有了显著增加，2013年的调查估计全球能力为15亿剂季节性疫苗和62亿剂大流行疫苗。本次调查结果显示，全球季节性流感疫苗产能自2013年以来已从15.04亿剂下降至14.67亿剂。然而，尽管全球季节性疫苗生产能力总体下降，但生产能力的分布出现了显著的积极变化，东南亚和西太平洋地区的生产能力有所增加，尽管规模较小。尽管季节性产能有所下降，但全球大流行性流感疫苗的产能从2013年的62亿剂增加到2015年的64亿剂。这种增长可归因于向更多四价疫苗生产的转变以及佐剂使用的增加。大流行性流感疫苗的生产能力已达到有记录以来的最高水平，但在保持这一能力和确保在发生大流行病时向服务不足的地区提供疫苗方面仍然存在挑战。(C)2016年6月，作者。出版社：Elsevier Ltd
A global shortage and inequitable access to influenza vaccines has been cause for concern for developing countries who face dire consequences in the event of a pandemic. The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 to increase global capacity for influenza vaccine production to address these concerns. It is widely recognized that well-developed infrastructure to produce seasonal influenza vaccines leads to increased capacity to produce pandemic influenza vaccines. This article summarizes the results of a survey administered to 44 manufacturers to assess their production capacity for seasonal influenza and pandemic influenza vaccine production. When the GAP was launched in 2006, global production capacity for seasonal and pandemic vaccines was estimated to be 500 million and 1.5 billion doses respectively. Since 2006 there has been a significant increase in capacity, with the 2013 survey estimating global capacity at 1.5 billion seasonal and 6.2 billion pandemic doses. Results of the current survey showed that global seasonal influenza vaccine production capacity has decreased since 2013 from 1.504 billion doses to 1.467 billion doses. However, notwithstanding the overall global decrease in seasonal vaccine capacity there were notable positive changes in the distribution of production capacity with increases noted in South East Asia (SEAR) and the Western Pacific (WPR) regions, albeit on a small scale. Despite a decrease in seasonal capacity, there has been a global increase of pandemic influenza vaccine production capacity from 6.2 billion doses in 2013 to 6.4 billion doses in 2015. This growth can be attributed to a shift towards more quadrivalent vaccine production and also to increased use of adjuvants. Pandemic influenza vaccine production capacity is at its highest recorded levels however challenges remain in maintaining this capacity and in ensuring access in the event of a pandemic to underserved regions. (C) 2016 The Authors. Published by Elsevier Ltd.